Catalyst Pharmaceuticals Reports $152.6M Q4 Sales, 19.8% Annual Growth to $589M, 2026 Forecast $615M-$645M
Catalyst Pharmaceuticals reported record full-year 2025 revenues of $589 million, up 19.8% year-over-year, and fiscal Q4 sales of $152.6 million. Management projected 2026 revenues between $615 million and $645 million, citing FIRDAPSE growth of 18.3% and AGAMREE growth of 67.5%.
1. Record Q4 and Full-Year Performance
Catalyst Pharmaceuticals achieved record full-year 2025 revenues of $589 million, representing 19.8% growth year-over-year, and a fiscal Q4 revenue of $152.6 million. These results mark consecutive years of record revenues driven by organic product momentum.
2. Product Portfolio Growth
FIRDAPSE sales increased by 18.3% in Q4, while AGAMREE sales surged 67.5%, reflecting accelerating adoption in existing and new markets. Fycompa remained a revenue contributor although faced with generic competition, supporting overall portfolio resilience.
3. 2026 Revenue Outlook
For full-year 2026, the company forecasts revenues between $615 million and $645 million, reflecting confidence in continued FIRDAPSE and AGAMREE traction. Management highlighted ongoing initiatives to expand patient identification, improve treatment persistence and deepen market penetration.